RÉSUMÉ
A 2-year and 4-month-old boy developed Langerhans cell histiocytosis (LCH) at the left parietal region of the skull. After treatment with chemotherapy, the patient achieved remission but experienced three relapses. After 3 years, he complained of headache, blurred vision, and lethargy. Brain magnetic resonance imaging revealed multiple dura-based meningeal masses. Biopsy was performed, and the patient was then diagnosed with juvenile xanthogranuloma (JXG). The analysis of both LCH/JXG tissues revealed BRAF V600E mutation. The JXG masses were not responsive to prednisolone, which was injected locally, radiotherapy (24 Gy), and chemotherapy (2-chlorodeoxy-adenosine). In addition, since the patient developed macrophage activation syndrome associated with systemic JXG progression, he received unrelated cord blood transplantation (u-CBT) at the age of 10 years and 11 months. Engraftment was performed at day 42, and significant GVHD was not observed. Four months after CBT, the patient was treated with infliximab (Remicade®) and dexamethasone palmitate (Limethasone®). The size of the intracranial JXG masses gradually decreased after u-CBT and disappeared after 4 years. Currently, the patient is doing well at the age of 25 years and is receiving androgen replacement therapy.
Sujet(s)
Transplantation de cellules souches de sang du cordon , Histiocytose à cellules de Langerhans , Xanthome juvénile , Encéphale , Humains , Nourrisson , Imagerie par résonance magnétique , Mâle , Xanthome juvénile/thérapieRÉSUMÉ
Endothelial like cells (ELCs) are thought to originate from either a hierarchy of endothelial progenitor cells (EPC), monocytes or monocyte derived multipotent progenitor cells (MOMCs). In this report, the ability of CD34(+) cells to generate ELC in vivo was examined using an immunodeficient mouse transplant assay system. The Philadelphia chromosome negative (Ph(-)) myeloproliferative neoplasms (MPN) are associated with the acquired mutation, JAK2V617F. In order to further examine the ability of cord blood and JAK2V617F positive MPN CD34(+) cells to generate ELC, CD34(+) cells were transplanted into NOD/SCID mice. Cells within the livers and lungs of recipient mice had phenotypic and molecular properties of human ELC as examined using RT-PCR, flow cytometric analysis and fluorescence microscopy. These cells possessed either human wild type JAK2 or JAK2V617F indicating that they were derived from the transplanted human cells and that a fraction of such cells were involved by the malignant process. Furthermore, human CD144(+) cells isolated from the livers of recipient mice formed clusters in vitro composed of ELC, which contained either wild type JAK2 or JAK2V617F suggesting that these cells are derived from either MOMC or EPC that have an extensive proliferative capacity as well as some degree of self renewal capacity. These studies indicate that adult CD34(+) cells can be affected by JAK2V617F and that they can generate ELC which might play a role in the development of thrombosis in patients with MPN.
Sujet(s)
Différenciation cellulaire , Cellules endothéliales/enzymologie , Kinase Janus-2/métabolisme , Leucémie myéloïde chronique BCR-ABL positive/enzymologie , Animaux , Antigènes CD34/analyse , Antigènes CD34/métabolisme , Cellules souches hématopoïétiques/enzymologie , Humains , Leucémie myéloïde chronique BCR-ABL positive/génétique , Foie/enzymologie , Poumon/enzymologie , Souris , Souris de lignée NOD , Souris SCID , Chromosome PhiladelphieRÉSUMÉ
The abnormal trafficking of CD34+ cells is a unique characteristic of primary myelofibrosis (PMF). We have further studied the behavior of PMF CD34+ cells by examining their homing to the marrow and the spleens of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Following the infusion of PMF and normal granulocyte colony-stimulating factor-mobilized peripheral blood (mPB) CD34+ cells into NOD/SCID mice, reduced numbers of PMF CD34+ cells and granulocyte-macrophage colony-forming unit (CFU-GM) compared with mPB were detected in the marrow of these mice, whereas similar numbers of PMF and mPB CD34+ cells and CFU-GM homed to their spleens. The abnormal homing of PMF CD34+ cells was associated with reduced expression of CXCR4, but was not related to the presence of JAK2V617F. The sequential treatment of PMF CD34+ cells with the chromatin-modifying agents 5-aza-2'-deoxycytidine (5azaD) and trichostatin A (TSA), but not treatment with small molecule inhibitors of JAK2, resulted in the generation of increased numbers of CD34+CXCR4+ cells, which was accompanied by enhanced homing of PMF CD34+ cells to the marrow but not the spleens of NOD/SCID mice. Following 5azaD/TSA treatment, JAK2V617F-negative PMF hematopoietic progenitor cells preferentially homed to the marrow but not the spleens of recipient mice. Our data suggest that PMF CD34+ cells are characterized by a reduced ability to home to the marrow but not the spleens of NOD/SCID mice and that this homing defect can be corrected by sequential treatment with chromatin-modifying agents.
Sujet(s)
Azacitidine/analogues et dérivés , Chromatine/effets des médicaments et des substances chimiques , Acides hydroxamiques/pharmacologie , Myélofibrose primitive/traitement médicamenteux , Myélofibrose primitive/anatomopathologie , Animaux , Antigènes CD34/biosynthèse , Azacitidine/pharmacologie , Moelle osseuse/anatomopathologie , Décitabine , Régulation négative , Humains , Souris , Souris de lignée NOD , Souris SCID , Myélofibrose primitive/métabolisme , Récepteurs CXCR4/biosynthèse , Rate/anatomopathologieRÉSUMÉ
Pruritus is a common symptom in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPDs). The pathophysiology of MPD-associated pruritus is unclear. We have demonstrated that MPD mast cells (MCs) are involved by the malignant process. In the present study, we explored the hypothesis that MCs play an important role in the development of pruritogenesis in MPDs. We found that MPD MCs released significantly greater amounts of pruritogenic factors, including histamine, leukotrienes, and interleukin-31 (IL-31) than normal MCs. Elevated levels of IL-31 were also observed in MPD CD3(+) cell-conditioned media. MPD MCs exhibited increased migratory behavior in response to stem cell factor or interleukin-8, which was associated with increased filamentous-actin content. Furthermore, the presence of pruritus in MPDs was statistically correlated with a greater number of MCs being generated by CD34(+) cells, a greater number of MC colonies being formed by CD34(+) cells, decreased apoptosis and prostaglandin D(2) release by cultured MCs, and higher plasma levels of IL-31. These data demonstrate that functional abnormalities of MPD MCs probably lead to pruritogenesis in patients with MPDs. These studies provide cellular and molecular targets for the development of antipruritus drugs for patients with MPDs.
Sujet(s)
Mastocytes/métabolisme , Syndromes myéloprolifératifs/métabolisme , Actines/métabolisme , Allèles , Mouvement cellulaire , Histamine/métabolisme , Humains , Interleukine-4/sang , Interleukines/biosynthèse , Interleukines/sang , Kinase Janus-2/métabolisme , Leucotriènes/métabolisme , Mastocytes/cytologie , Syndromes myéloprolifératifs/anatomopathologie , Facteur de croissance nerveuse/sang , Prostaglandine D2/métabolisme , Tryptases/métabolismeRÉSUMÉ
Patients with infant acute myeloid leukemia (AML) who carry a t(7;12)(q36;p13) translocation have been reported to have a poor clinical outcome. MNX1-ETV6 fusion transcripts (previously HLXB9-ETV6) were rarely detected in AML patients having t(7;12)(q36;p13). A 23-month-old girl with acute megakaryoblastic leukemia (AMKL) exhibited chromosome abnormalities, including add(7)(q22), and del(12)(p12p13). Southern blot analysis of bone marrow cells showed an ETV6 gene rearrangement. Reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequence analysis revealed the presence of an MNX1-ETV6 fusion gene. The patient responded well to chemotherapy, achieved complete remission, and at writing had been in complete remission for 60 months. The MNX1 expression by RT-PCR was significantly more frequent in Epstein-Barr virus-transformed B-cell lines derived from normal adult lymphocytes than in leukemic cell lines. This represents a novel case of an AMKL patient with MNX1-ETV6 fusion transcripts who had a good prognosis.
Sujet(s)
Lymphocytes B/métabolisme , Fusion de gènes , Protéines à homéodomaine/génétique , Leucémie aigüe mégacaryoblastique/génétique , Leucémies/génétique , Protéines proto-oncogènes c-ets/génétique , Protéines de répression/génétique , Facteurs de transcription/génétique , Lignée cellulaire tumorale , Aberrations des chromosomes , Femelle , Humains , Nourrisson , RT-PCR ,RÉSUMÉ
The clinical course of patients with Philadelphia chromosome negative myeloproliferative disorder is frequently complicated by thrombotic events. Post-natal vasculogenesis has been proposed to play a critical role in angiogenesis by acting through a hierarchy of endothelial progenitor cells. Some endothelial progenitor cells have been shown to share a number of features associated with monocytes while other more primitive progenitor cells produce endothelial cells in vitro exclusively. The cells which share features of monocytes and endothelial cells have been termed angiogenic monocytes. Reduced levels of angiogenic monocyte progenitor cells have been reported to be predictive of atherosclerotic disease progression. Angiogenic monocyte progenitor cells were assayed in vitro from the peripheral blood mononuclear cells of myeloproliferative disorder patients. Angiogenic monocyte colonies were plucked and analyzed for endothelial cells and hematopoietic cell markers, JAK2V617F and their ability to incorporate into vascular endothelium following their transplantation into non-obese diabetic, severe combine immunodeficient mice. Myeloproliferative disorder angiogenic monocyte colonies that were detected were uniformly JAK2V617F positive and produced cells that expressed phenotypic markers characteristic of both monocytes and endothelial cells. Reduced numbers of angiogenic monocyte colonies were present in the blood of myeloproliferative disorder patients with a high JAK2V617F burden (>50%), (p<0.01). Transplanted angiogenic monocytes were able to contribute to the vascular endothelium of non-obese diabetic, severe combine immunodeficient mice. These studies suggest that reduced numbers of circulating angiogenic monocyte progenitors contribute to the propensity to develop thrombotic complications in myeloproliferative disorder patients.
Sujet(s)
Monocytes/physiologie , Syndromes myéloprolifératifs/génétique , Cellules souches/physiologie , Allèles , Animaux , Acide acétylsalicylique/métabolisme , Athérosclérose , Circulation sanguine , Cellules cultivées , Test clonogénique , Association médicamenteuse , Humains , Souris , Néovascularisation physiologique , Acide succinique/métabolismeRÉSUMÉ
OBJECTIVE: We investigated if polycythemia vera (PV) peripheral blood (PB) CD34+ cells contain cells capable of engrafting nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice and if the JAK2V617F mutational burden of these cells alters their behavior in NOD/SCID mice. MATERIALS AND METHODS: CD34+ cells isolated from patients with PV, idiopathic myelofibrosis (IM), or granulocyte colony-stimulating factor-mobilized normal donors were transplanted into sublethally irradiated NOD/SCID mice. Cells engrafted into the NOD/SCID mice were analyzed flow cytometrically using lineage-specific antibodies. Genomic DNA was extracted from granulocytes, CD34+ cells, and sorted human CD45(+) cells purified from the bone marrow cells of these mice to examine their JAK2V617F mutational burdens. RESULTS: Multilineage human cell engraftment was observed in mice transplanted with CD34+ cells from mobilized normal volunteers, IM patients and PV patients with high JAK2V617F burden, but not in mice receiving grafts from PV patients with low JAK2V617F burden. The differentiation program of engrafting PV CD34+ cells with high JAK2V617F burden was remarkably different than that of IM CD34+ cells. The JAK2V617F allele frequency in the human CD45+ cells isolated from the mice receiving CD34+ cells was lower than that observed in the CD34+ cell grafts, indicating the persistence of a JAK2V617F negative compartment of stem cells. CONCLUSION: We conclude that PB CD34+ cells from PV patients with high JAK2V617F burden and patients with IM contain NOD/SCID repopulating cells, and that differentiation program of IM and PV CD34+ cells are dramatically different.
Sujet(s)
Transplantation de cellules souches hématopoïétiques , Cellules souches hématopoïétiques/anatomopathologie , Kinase Janus-2/génétique , Mutation faux-sens/physiologie , Polyglobulie primitive essentielle/anatomopathologie , Animaux , Antigènes CD34 , Études cas-témoins , Lignage cellulaire , Survie du greffon , Humains , Souris , Souris de lignée NOD , Souris SCID , Myélofibrose primitive/anatomopathologie , Transplantation hétérologueRÉSUMÉ
Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2'-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34(+) cells. Unlike normal CD34(+) cells where 5azaD/TSA treatment leads to the expansion of CD34(+) cells and marrow-repopulating cells, treatment of IM CD34(+) cells results in a reduction of the number of total cells, CD34(+) cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34(+) cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617F-positive HPCs in 83% of the patients studied and the reduction in the proportion of homozygous HPCs in 50% of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34(+) cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34(+) cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM.
Sujet(s)
Antigènes CD34/biosynthèse , Antimétabolites antinéoplasiques/pharmacologie , Azacitidine/analogues et dérivés , Chromatine/composition chimique , Chromatine/métabolisme , Acides hydroxamiques/pharmacologie , Myélofibrose primitive/sang , Myélofibrose primitive/traitement médicamenteux , Inhibiteurs de la synthèse protéique/pharmacologie , Antigènes CD34/métabolisme , Azacitidine/pharmacologie , Mouvement cellulaire , DNA (cytosine-5-)-methyltransferase/métabolisme , Décitabine , Cellules souches hématopoïétiques/métabolisme , Homozygote , Humains , Mutation , Récepteurs CXCR4/métabolisme , Cellules souches/métabolismeRÉSUMÉ
In order to investigate the biologic processes underlying and resulting from the megakaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34+ cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF-mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34+ cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34+ cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61+ cells generated in vitro from CD34+ cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-beta (TGF-beta) and active matrix metalloproteinase-9 (MMP9) were observed in media conditioned with IMF CD61+ cells than normal or PV CD61+ cells. Both normal and IMF CD61+ cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.
Sujet(s)
Cellules souches hématopoïétiques/métabolisme , Matrix metalloproteinase 9/biosynthèse , Mégacaryocytes/métabolisme , Myélofibrose primitive/métabolisme , Facteur de croissance transformant bêta/biosynthèse , Facteur de croissance endothéliale vasculaire de type A/biosynthèse , Adulte , Sujet âgé , Antigènes CD34 , Apoptose/effets des médicaments et des substances chimiques , Cellules cultivées , Milieux de culture conditionnés , Femelle , Facteur de stimulation des colonies de granulocytes/pharmacologie , Mobilisation de cellules souches hématopoïétiques , Cellules souches hématopoïétiques/anatomopathologie , Humains , Hyperplasie/métabolisme , Hyperplasie/anatomopathologie , Intégrine bêta3/métabolisme , Mâle , Mégacaryocytes/anatomopathologie , Adulte d'âge moyen , Polyglobulie primitive essentielle/métabolisme , Polyglobulie primitive essentielle/anatomopathologie , Myélofibrose primitive/anatomopathologie , Thrombopoïétine/pharmacologie , Protéine bcl-X/métabolismeRÉSUMÉ
JAK2(V617F), a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The JAK2 mutant displays a much increased kinase activity and generates a PV-like phenotype in mouse bone marrow transplant models. This study shows that the anti-cancer drug erlotinib (Tarceva) is a potent inhibitor of JAK2(V617F) activity. In vitro colony culture assays revealed that erlotinib at micro-molar concentrations effectively suppresses the growth and expansion of PV hematopoietic progenitor cells while having little effect on normal cells. Furthermore, JAK2(V617F)-positive cells from PV patients show greater susceptibility to the inhibitor than their negative counterparts. Similar inhibitory effects were found with the JAK2(V617F)-positive human erythroleukemia HEL cell line. These data suggest that erlotinib may be used for treatment of JAK2(V617F)-positive PV and other myeloproliferative disorders.
Sujet(s)
Substitution d'acide aminé/génétique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Inhibiteurs de croissance/pharmacologie , Kinase Janus-2/antagonistes et inhibiteurs , Kinase Janus-2/métabolisme , Polyglobulie primitive essentielle/enzymologie , Polyglobulie primitive essentielle/anatomopathologie , Quinazolines/pharmacologie , Animaux , Lignée cellulaire tumorale , Systèmes de délivrance de médicaments , Activation enzymatique/effets des médicaments et des substances chimiques , Activation enzymatique/génétique , Chlorhydrate d'erlotinib , Cellules souches hématopoïétiques/effets des médicaments et des substances chimiques , Cellules souches hématopoïétiques/enzymologie , Cellules souches hématopoïétiques/anatomopathologie , Humains , Cellules Jurkat , Souris , Phénylalanine/génétique , Polyglobulie primitive essentielle/traitement médicamenteux , Polyglobulie primitive essentielle/génétique , Inhibiteurs de protéines kinases/pharmacologie , Valine/génétiqueRÉSUMÉ
The JAK2(V617F) mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33+, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2(V617F) mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2(V617F) mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2(V617F) mutation decreased after differentiation of CD34+ cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2(V617F) mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2(V617F) mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.
Sujet(s)
Cellules souches hématopoïétiques/physiologie , Kinase Janus-2/génétique , Mutation , Polyglobulie primitive essentielle/génétique , Substitution d'acide aminé , Antigènes CD/analyse , Amorces ADN , Glycophorines/analyse , Granulocytes/physiologie , Cellules souches hématopoïétiques/enzymologie , Humains , Kinase Janus-2/composition chimique , Réaction de polymérisation en chaîne , Valeurs de référenceRÉSUMÉ
Most cases of nephrotic syndrome following stem cell transplantation (SCT) occur 6 months after SCT. The patients are treated with immunosuppressive therapies; however, in some cases treatment is not effective. We used enalapril, an angiotensin-converting enzyme inhibitor (ACEI) and candesartan, an angiotensin II receptor blocker (ARB), for the control of proteinuria in a case of immunosuppressive treatment (IST)-resistant nephrotic syndrome. A 15-year-old boy with acute lymphoblastic leukemia underwent allogeneic peripheral blood SCT from a completely HLA-matched sibling after completion of a conditioning regimen composed of 12-Gy doses of total-body irradiation, 600 mg/m2 thiotepa, and 140 mg/m2 melphalan. Twenty-eight months after SCT, minimal-change nephrotic syndrome was diagnosed on the basis of biopsy findings. Although neither cyclosporine (trough level, 100-150 ng/mL) nor corticosteroid was effective, proteinuria disappeared 2 months after the beginning of treatment with tacrolimus (trough level, 13-20 ng/mL), and remission was maintained for 23 months. Nephrotic syndrome recurred, however, and was resistant to tacrolimus. Findings at the second renal biopsy revealed membranous nephropathy. An ARB (candesartan, 4 mg/ day) in combination with an ACEI (enalapril, 5 mg/day) was started. Proteinuria improved within 2 weeks. We suggest that ARB combined with ACEI can be used to control proteinuria in patients with IST-resistant nephrotic syndrome after SCT.